Share
Print
Call Updates
We recently informed the applicants about the evaluation results for their proposals submitted under this topic. The results of the evaluation are as follows:
Sep 22, 2022 5:15:51 PM
Second stage of call HORIZON-HLTH-2022-DISEASE-06-two-stage closed on 6 September 2022. 67 proposals have been submitted. The breakdown per topic is:
Evaluation results are expected to be communicated on Friday 9 December 2022 at the earliest.
Jun 24, 2022 12:19:59 PM
Please consult the "Call updates" section for generalised feedback after stage 1.
Jun 24, 2022 12:19:59 PM
In order to best ensure equal treatment, successful stage 1 applicants do not receive the evaluation summary reports (ESRs) for their proposals, but this generalised feedback with information and tips for preparing the full proposal.
Information & tips
Main suggestions to stage 2 applicants:
In your stage 2 proposal, you have a chance to address or clarify these issues. Please bear in mind that your full proposal will now be evaluated more in-depth and possibly by a new group of outside experts.
Please make sure that your full proposal is consistent with your short outline proposal. It may NOT differ substantially. The project must remain the same.
Evaluation results for the second stage are expected to be communicated on Friday 9 December 2022 at the earliest.
Jun 1, 2022 5:07:56 PM
Topic specific evaluation results:
May 25, 2022 5:01:19 PM
In accordance with General Annex D of the Work Programme, the evaluation of the first-stage proposals was made looking only at the criteria 'excellence' and 'impact'. The threshold for both individual criteria is 4.
The overall threshold applying to the sum of the two individual scores was set at a level that ensures the total requested budget of proposals admitted to stage 2 is as close as possible to three times the available budget, and not less than two and a half times the available budget, and is as follows:
The results of the evaluation are:
Feb 8, 2022 4:41:50 PM
Call HORIZON-HLTH-2022-DISEASE-06-two-stage closed on 1 February 2022. 240 proposals have been submitted. The breakdown per topic is:
Evaluation results are expected to be communicated on Friday 20 May 2022 at the earliest.
Oct 6, 2021 12:00:01 AM
The submission session is now available for: HORIZON-HLTH-2022-DISEASE-06-03-two-stage(HORIZON-RIA)
Vaccines 2.0 - developing the next generation of vaccines
TOPIC ID: HORIZON-HLTH-2022-DISEASE-06-03-two-stage
Programme: Horizon Europe Framework Programme (HORIZON)
Call: Tackling diseases (Two Stage - 2022) (HORIZON-HLTH-2022-DISEASE-06-two-stage)
Type of action: HORIZON-RIA HORIZON Research and Innovation Actions
Type of MGA: HORIZON Action Grant Budget-Based [HORIZON-AG]
Deadline model: two-stage
Planned opening date: 06 October 2021
Deadline dates: 01 February 2022 17:00:00 Brussels time
06 September 2022 17:00:00 Brussels time
Topic description
ExpectedOutcome:
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:
Scope:
Infectious diseases, including antimicrobial resistant (AMR) infections, remain a major threat to health and health security in the EU and globally. The availability of more effective, accessible and affordable vaccines would provide the most cost-effective preventive measure against the health threat of epidemics and AMR pathogens. Vaccines against diseases, such as AIDS, tuberculosis (TB), malaria, neglected tropical diseases, hepatitis C and water-borne diseases are essential to achieve the WHO targets to control the spread of infectious diseases. The first generation of vaccines against some of the pathogens have proven to be suboptimal and not effective enough to protect the population. Many viruses of pandemic potential are variable in their surface antigen composition, and novel technologies are required to develop efficient vaccines against each new variant efficiently and in a short timeframe. To ensure that more effective, accessible and affordable vaccines against all major infectious diseases become a reality, it is essential to sustain a diverse and modernised vaccine development pipeline.
Proposals should aim to diversify and accelerate the global vaccine research and development pipeline, and to strengthen the current leading role of the EU in vaccine research and development. Proposals should cover those pathogens, which still lack vaccines of sufficient efficacy, but where earlier efforts have already produced promising vaccine candidates.
The proposals should address several of the following areas:
Cross-cutting Priorities:
Socio-economic science and humanities